Published in Annu Rev Med on January 14, 2016
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | NCT01349959
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma | NCT01524991
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00323882
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer | NCT01105377
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | NCT00425555
PXD101 in Treating Patients With Acute Myeloid Leukemia | NCT00357032
Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter | NCT01900730
Targeting the cancer epigenome for therapy. Nat Rev Genet (2016) 1.01
Epigenetic control of adult stem cell function. Nat Rev Mol Cell Biol (2016) 0.88
Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Res (2017) 0.79
Sexual dimorphism in cancer. Nat Rev Cancer (2016) 0.78
Transcription factor LSF-DNMT1 complex dissociation by FQI1 leads to aberrant DNA methylation and gene expression. Oncotarget (2016) 0.77
Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci (2017) 0.77
Translating HDAC inhibitors in Friedrich's ataxia. Expert Opin Orphan Drugs (2016) 0.75
Understanding specific functions of PARP-2: new lessons for cancer therapy. Am J Cancer Res (2016) 0.75
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int (2016) 0.75
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics (2017) 0.75
Pan-cancer analysis of frequent DNA co-methylation patterns reveals consistent epigenetic landscape changes in multiple cancers. BMC Genomics (2017) 0.75
Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B. Hepatology (2017) 0.75
A key HDAC6 dependency of ARID1A-mutated ovarian cancer. Nat Cell Biol (2017) 0.75
Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Semin Liver Dis (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The epigenomics of cancer. Cell (2007) 30.91
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
The complex language of chromatin regulation during transcription. Nature (2007) 16.97
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Lessons from the cancer genome. Cell (2013) 8.12
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature (2008) 7.64
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Epigenetic regulation by long noncoding RNAs. Science (2012) 4.74
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
An operational definition of epigenetics. Genes Dev (2009) 4.26
Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell (2013) 4.16
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol (2014) 3.62
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
DNA methylation, methyltransferases, and cancer. Oncogene (2001) 3.30
TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol (2013) 3.18
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol (2005) 3.05
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev (2007) 2.95
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2015) 2.60
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell (2015) 2.45
Polycomb group protein-mediated repression of transcription. Trends Biochem Sci (2010) 2.37
Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 2.11
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov (2012) 1.81
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
A new world of Polycombs: unexpected partnerships and emerging functions. Nat Rev Genet (2013) 1.67
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
DNA methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos. Genes Dev (2014) 1.55
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer (2011) 1.51
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol (2004) 1.50
Demethylating agents in myeloid malignancies. Curr Opin Oncol (2008) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
Notes on the role of dynamic DNA methylation in mammalian development. Proc Natl Acad Sci U S A (2014) 1.36
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev (2012) 1.32
DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol (2000) 1.31
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol (2014) 1.23
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia (2006) 1.22
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. Neuropharmacology (2012) 1.19
Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol (2014) 1.18
HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res (2012) 1.15
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol (2005) 1.11
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol (2015) 1.08
Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. J Neuropathol Exp Neurol (2013) 1.06
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene (2013) 1.05
Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
Using genetic diagnosis to determine individual therapeutic utility. Annu Rev Med (2010) 0.90
DNA methylation in the treatment of hematologic malignancies. Clin Adv Hematol Oncol (2005) 0.81
Oxygen concentration controls epigenetic effects in models of familial paraganglioma. PLoS One (2015) 0.80
The emerging molecular machinery and therapeutic targets of metastasis. Trends Pharmacol Sci (2015) 0.80
Epigenetics of Alzheimer's disease and frontotemporal dementia. Neurotherapeutics (2013) 0.80
Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharm Pat Anal (2015) 0.79
Histone H3 mutations in pediatric brain tumors. Cold Spring Harb Perspect Biol (2014) 0.77